225 related articles for article (PubMed ID: 28025724)
21. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
Wang D; Kowalewski EK; Koch G
Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
[TBL] [Abstract][Full Text] [Related]
22. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease.
Ketter N; Liu E; Di J; Honig LS; Lu M; Novak G; Werth J; LePrince Leterme G; Shadman A; Brashear HR
J Prev Alzheimers Dis; 2016; 3(4):192-201. PubMed ID: 29199321
[TBL] [Abstract][Full Text] [Related]
23. Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
Lu L; Zheng X; Wang S; Tang C; Zhang Y; Yao G; Zeng J; Ge S; Wen H; Xu M; Guyatt G; Xu N
J Neurol Neurosurg Psychiatry; 2020 Dec; 91(12):1316-1324. PubMed ID: 33046560
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: A systematic review and network meta-analysis.
Foroutan N; Hopkins RB; Tarride JE; Florez ID; Levine M
Clin Invest Med; 2019 Mar; 42(1):E53-E65. PubMed ID: 30904037
[TBL] [Abstract][Full Text] [Related]
25. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Rogers SL
Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
[TBL] [Abstract][Full Text] [Related]
26. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
[TBL] [Abstract][Full Text] [Related]
27. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
van Dyck CH
Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385
[TBL] [Abstract][Full Text] [Related]
28. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
29. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.
Zago W; Schroeter S; Guido T; Khan K; Seubert P; Yednock T; Schenk D; Gregg KM; Games D; Bard F; Kinney GG
Alzheimers Dement; 2013 Oct; 9(5 Suppl):S105-15. PubMed ID: 23583235
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis.
Wang BS; Wang H; Wei ZH; Song YY; Zhang L; Chen HZ
J Neural Transm (Vienna); 2009 Apr; 116(4):457-65. PubMed ID: 19221692
[TBL] [Abstract][Full Text] [Related]
31. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models.
Busche MA; Grienberger C; Keskin AD; Song B; Neumann U; Staufenbiel M; Förstl H; Konnerth A
Nat Neurosci; 2015 Dec; 18(12):1725-7. PubMed ID: 26551546
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
Jiang D; Yang X; Li M; Wang Y; Wang Y
J Neural Transm (Vienna); 2015 Aug; 122(8):1157-66. PubMed ID: 25547862
[TBL] [Abstract][Full Text] [Related]
33. Differences in Alzheimer disease clinical trial outcomes based on age of the participants.
Schneider LS; Kennedy RE; Wang G; Cutter GR
Neurology; 2015 Mar; 84(11):1121-7. PubMed ID: 25681452
[TBL] [Abstract][Full Text] [Related]
34. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW
Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577
[TBL] [Abstract][Full Text] [Related]
35. Disease-modifying therapies in Alzheimer's disease: how far have we come?
Hüll M; Berger M; Heneka M
Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
[TBL] [Abstract][Full Text] [Related]
36. Amyloid beta peptide immunotherapy in Alzheimer disease.
Delrieu J; Ousset PJ; Voisin T; Vellas B
Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
[TBL] [Abstract][Full Text] [Related]
37. [Aβ immunotherapy for Alzheimer's disease].
Sakai K; Yamada M
Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
[TBL] [Abstract][Full Text] [Related]
38. Current treatment of mild cognitive impairment and Alzheimer's disease.
Knopman DS
Curr Neurol Neurosci Rep; 2006 Sep; 6(5):365-71. PubMed ID: 16928345
[TBL] [Abstract][Full Text] [Related]
39. Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-Aβ autoantibodies.
Boncoraglio GB; Piazza F; Savoiardo M; Farina L; DiFrancesco JC; Prioni S; Tagliavini F; Parati EA; Giaccone G
J Alzheimers Dis; 2015; 45(2):363-7. PubMed ID: 25537009
[TBL] [Abstract][Full Text] [Related]
40. Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects.
Kozin SA; Barykin EP; Mitkevich VA; Makarov AA
Biochemistry (Mosc); 2018 Sep; 83(9):1057-1067. PubMed ID: 30472944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
